A new, real-world evidence study of patients with Gram-negative infections showed that early intervention with Fetroja® (cefiderocol) significantly reduced in-hospital all-cause mortality. This real-world evidence, drawn from a retrospective analysis of 275 seriously ill patients, emphasizes the critical importance of timely treatment. The retrospective multicenter observational study showed earlier treatment resulted in a reduction in in-hospital all-cause mortality (IHACM) in patients with Gram-negative infections who previously received other antibiotics, including those with difficult-to-treat pathogens that were resistant to other antibiotics. Here is a link to the press release with a summary of the results presented by Shionogi at ID Week in October.
We interview Thomas Lodise, PharmD, PhD, Associate Professor, Albany College of Pharmacy and Health Sciences, to delve deeper into these results. Dr. Lodise discusses the implications of this study for hospital pharmacists as it sheds light on the potential clinical utility of Fetroja in the treatment of difficult-to-treat adult patients with culture-confirmed Gram-negative infections.

Time-to-Treat Proves to be Vital in Severely Ill Patients With Gram-Negative Infections

https://urldefense.com/v3/__https:/www.contagionlive.com/view/time-to-treat-proves-to-be-vital-in-severely-ill-patients-with-gram-negative-infections__;!!DlCMXiNAtWOc!xSJ9qL-jtnTrARykD5XxP6jzP-M_Tt38Tki6NjQCLr2AStUrVu6HBFK3hTU5Y32uJwR2_8AQu_cWgSu7Z6Oep2zcAqnNBtu4BA$ New boost

TWIRx | Treating Gram-Negative Bacterial Infections with Thomas Lodise, PharmD, PhD